They Built a Hemp Business in Good Faith but Washington Is About To Crush It

A provision buried in the federal continuing resolution would cap total THC in any consumable hemp product at 0.4 mg per container—a change industry advocates say could eliminate roughly 95% of U.S. hemp-derived cannabinoid products. The move compounds state-level restrictions (e.g., Tennessee's 2025 law forcing a three-tier distribution system effective January 2026), threatening out-of-state producers such as Cornbread Hemp; U.S. industrial hemp value fell from about $824M in 2021 to ~$445M in 2024, with industry estimates of roughly 325,000 related jobs. Legal challenges are already underway, but the combined federal and state regulatory pressure materially raises regulatory and commercial risk for hemp producers and retailers.

Analysis

Market structure: The 0.4 mg/container rule is a shock that functionally removes ~95% of current hemp consumables, stripping scale from small CBD/topical brands and forcing product exits or reformulations within 3–6 months. Winners will be state-licensed THC MSOs and in-state wholesalers/retail chains that can capture displaced demand and distribution margins; expect gross-margin compression for remaining small producers and double-digit price increases for compliant niche SKUs as supply tightens.

Risk assessment: Tail risks include a full federal ban (low probability, high impact) or successful legal reversal (medium probability) — either can swing valuations ±50–100% for exposed names. Immediate (days) will see idiosyncratic equity volatility; short-term (weeks–months) will produce liquidity stress and bankruptcies among small caps; long-term (quarters–years) drives consolidation and M&A by well-capitalized MSOs.

Trade implications: Practical trades: long large MSOs and state-legal retailers (scale over 3–12 months), short OTC hemp product issuers and small-cap consumer names now facing revenue collapse. Use options to hedge timing risk (buy 3–6 month puts on sector ETF MJ for downside protection; buy 6–12 month call spreads on selected MSOs to play consolidation upside).

Contrarian angles: Consensus underestimates black-market and pharma pivots — illicit THC channels will grow and synthetic/specialty cannabinoid biotech could capture demand, creating acquisition targets. Reaction is likely overdone in OTC hemp equities (many will go to zero), creating M&A pick-up opportunities for large MSOs to buy brands at 50–80% discounts once near-term regulatory noise stabilizes.

Key Decisions for Investors

• Establish a 2–3% portfolio long split: 60% Curaleaf (CURLF) and 40% Tilray (TLRY), scale into positions over 3 months on any 10% pullback; target 12–18 month hold aiming for 30–70% upside if consolidation accelerates.
• Initiate a 1–2% short position in OTC hemp consumer equities (e.g., Hemp, Inc. OTC: HEMP) via shares or 3-month puts where liquid; set stop-loss at 25% adverse move and target 50–80% downside as revenues collapse under the new rule.
• Buy 3–6 month ATM put protection on the MJ ETF (ticker: MJ) sized to cover 1–2% of portfolio exposure to cannabis sector; this hedges near-term regulatory-driven volatility while preserving upside exposure in selected longs.
• Allocate 1–2% dry powder for event-driven M&A opportunities: commit to deploy within 6–18 months to acquire distressed hemp brands or IP if valuations fall >60% and revenue erosion exceeds 50%—target entry valuations at EV/EBITDA <2x or distressed asset sales.